Edison Investment Research - CytRx Corporation (CYTR) Update: Aldoxorubicin trials resume as clinical hold lifted

Report

Edison Investment Research

Update: Aldoxorubicin trials resume as clinical hold lifted

The lifting of a partial clinical hold imposed on aldoxorubicin improves clarity on its future development and enables the firm to maintain its existing timeline projections for the ongoing clinical trials. CytRx is confident its funds on hand should be sufficient to reach top-line data in mid-2016 from its Phase III study in second-line soft tissue sarcoma (STS).

25/02/2015 7 EN

Underlying

CytRx Corporation

See profile

US2328285091 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

InsiderInsights.com

InsiderInsights Daily Ratings Report: August 20, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Free Trial

August 20, 2020 August 20, 2020 5 EN

MarketLine

CytRx Corporation â€“ Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

EUR 311.72

June 12, 2017 June 12, 2017 86 EN

SmartInsider

Insider bought: A director bought 2,325,581 shares at 0.430USD and

A director at Cytrx Corp bought 2,325,581 shares at 0.430USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Free Trial

December 21, 2016 December 21, 2016 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

17h / 52m 17h / 52m 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

19h / 46m 19h / 46m 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

21h / 13m 21h / 13m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN